secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immuneering Corp (IMRX)
CIK:        0001790340
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001790340-24-000054
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immuneering reports Q1 net loss $14.3M; Phase 2a data for IMM-1-104 expected in 2024
--------------------------------------------------------------------------------

- Net loss $14.3M ($0.49/share) vs $13.6M ($0.51) Q1 2023; R&D expense $11.2M up from $10.2M.
- Phase 1 data for IMM-1-104 shows well-tolerated safety; target lesion regression in >50% of patients at 320mg.
- First patient dosed in Phase 2a of IMM-1-104; initial data from multiple arms expected in 2024.
- First patient dosed in Phase 1/2a of IMM-6-415 (RAF/RAS mutations); initial PK/PD/safety data expected 2024.
- FDA Fast Track designation for IMM-1-104 in pancreatic cancer; cash $71.3M expected to fund operations into H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1790340/000179034024000054/0001790340-24-000054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1790340/000179034024000054/imrx-20240507.htm
  HTML page:      https://secwatch.observer/filing/0001790340-24-000054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer